Acute lymphocytic leukemia (ALL), also known as acute lymphoblastic leukemia, is a cancer of the blood and bone marrow.
According to the American Cancer Society, about 5,960 new cases of acute lymphoblastic leukemia (ALL) will be diagnosed in the U.S. this year. Estimates of complete remission range from approximately 80-90 percent of adults diagnosed with ALL. Despite these rates, a large portion of these patients will relapse. For patients that relapse, prognostic factors become critical to help determine treatment decisions. Relevant factors in post-remission prognosis include white blood cell count at diagnosis, disease subtype, and time it took for the patient to achieve complete remission. Additionally, minimal residual disease (MRD) has emerged as a prognostic factor. Quantification of MRD can provide insight into risk/benefit stratification and allow the cancer care team to make patient-specific therapeutic selections.
The ACCC Multidisciplinary Acute Lymphocytic Leukemia Care education project seeks to identify key barriers to and opportunities for improvement in the cancer care team’s support of patients diagnosed with ALL, including utilization of MRD testing, detection, and monitoring. Through this project, ACCC aims to:
ASH 2018 Update Webinar
Supporting the Patient Journey: A Closer Look at Adult ALL
Critical Insights for Treating Adults with ALL in the Community
ACCC prepared an environmental scan for this project that provides an overview of the current landscape for ALL diagnosis and care management and information on treatment advances for this patient population.
The scan also highlights potential process improvement opportunities in areas such as provider-to-provider communication, co-management of patients, shared decision-making, minimal residual disease testing, and side effect management.
Download Environmental Scan